Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in active ankylosing spondylitis
NCT02159053Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2015
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in ankylosing spondylitis (AS) (3 arms), sponsored by Novartis. Primary endpoint: Assessment of SpondyloArthritis international Society 20 Response at 16 weeks. Started May 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02159053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159053.